AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Millendo Therapeutics to Participate in May Investor Conferences

May 2, 2019

ANN ARBOR, Mich.--(BUSINESS WIRE)--May 2, 2019--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews at the following healthcare investor conferences:

  • 2019 SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on Tuesday, May 7, 2019 in New York, where one-on-one investor meetings will be held.
  • 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 10:00 a.m. EST in New York. A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit  www.millendo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005167/en/

CONTACT: Millendo Investor Contact:

Stephanie Ascher

Stern Investor Relations

212-362-1200

stephanie.ascher@sternir.com

Millendo Media Contact:

Betsy Yates

MacDougall

781-235-3094

byates@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Millendo Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 05/02/2019 08:30 AM/DISC: 05/02/2019 08:30 AM

http://www.businesswire.com/news/home/20190502005167/en